Celldex Therapeutics (NASDAQ:CLDX) Upgraded at Barclays

Barclays upgraded shares of Celldex Therapeutics (NASDAQ:CLDX) from an underweight rating to an overweight rating in a research note released on Monday morning, MarketBeat Ratings reports. They currently have $45.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $24.00.

Several other research analysts also recently issued reports on CLDX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Wednesday, January 21st. Stifel Nicolaus reiterated a “buy” rating and issued a $68.00 target price (up from $58.00) on shares of Celldex Therapeutics in a research note on Thursday, February 26th. Wolfe Research upgraded shares of Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 target price on the stock in a research note on Monday, March 23rd. Finally, The Goldman Sachs Group upped their target price on shares of Celldex Therapeutics from $30.00 to $34.00 and gave the stock a “neutral” rating in a research note on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $46.36.

Celldex Therapeutics Price Performance

Shares of NASDAQ:CLDX opened at $34.21 on Monday. Celldex Therapeutics has a 1-year low of $17.85 and a 1-year high of $35.79. The business has a fifty day moving average price of $29.90 and a 200-day moving average price of $27.45. The company has a market capitalization of $2.28 billion, a PE ratio of -8.79 and a beta of 1.19.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.22). The firm had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $1.53 million. On average, sell-side analysts anticipate that Celldex Therapeutics will post -4.87 earnings per share for the current fiscal year.

Institutional Trading of Celldex Therapeutics

Large investors have recently added to or reduced their stakes in the business. Aster Capital Management DIFC Ltd bought a new stake in Celldex Therapeutics during the third quarter valued at approximately $26,000. Wilmington Savings Fund Society FSB bought a new stake in Celldex Therapeutics during the third quarter valued at approximately $42,000. Russell Investments Group Ltd. grew its position in Celldex Therapeutics by 27.6% during the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 501 shares during the period. Quantbot Technologies LP bought a new stake in Celldex Therapeutics during the third quarter valued at approximately $63,000. Finally, Strs Ohio bought a new stake in Celldex Therapeutics during the third quarter valued at approximately $75,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.